cropped-APARIENTE_été.jpg
Directeur – Equipe Pharmaco-épidémiologie

Médecin spécialiste en Santé Publique, Antoine Pariente a complété sa formation médicale en effectuant un cursus de spécialisation complémentaire en pharmacologie et évaluation des thérapeutiques. Parallèlement a ses études de médecine, il a suivi une formation à la recherche en santé publique  et obtenu un Master en Epidémiologie et biostatistique (Université de Bordeaux) avant de compléter une Thèse d’Université en Pharmaco-épidémiologie (Université de Bordeaux – Université de Montréal). Ses axes de recherche principaux sont la pharmaco-épidémiologie des personnes âgées et des maladies chroniques, et la détection de signaux en pharmacovigilance.

Graduated from the medical faculty of Bordeaux as an MD with specialisation in Public Health, A. Pariente completed his medical training with a complementary specialisation in Pharmacology. Concomitantly to his medical studies, he obtained a Master Degree in Public Health at the Bordeaux Institute of Public Health and further completed his research training with a PhD in pharmacoepidemiology (University of Bordeaux-University of Montreal). His main research axes in pharmacoepidemiology focus on the elder and chronic diseases ; they focus in methods and biases for safety signal detection from spontaneous reporting in pharmacovigilance.

 

Antoine Pariente est Praticien Hospitalier – Professeur des Universités à l’Université de Bordeaux. Il est directeur de l’équipe de recherche Inserm  Pharmaco-épidémiologie et Impact des Médicaments sur les Populations et responsable du Centre  Régional de Pharmacovigilance de Bordeaux.

Depuis 2015, il coordonne la plateforme de pharmaco-épidémiologie DRUGS-SAFE Drugs Systematised Assessment in real-liFe Environment dont la mission est la conduite d’études pharmaco-épidémiologiques sur demande de l’ANSM et le développement d’outils méthodologiques permettant d’améliorer la qualité de la recherche pouvant être conduite en pharmaco-épidémiologie à partir des bases de données de l’Assurance-Maladie.

 

Antoine Pariente is Professor of Medical Pharmacology at the University of Bordeaux. He is heading the « Pharmacoepidemiology and population impact of drugs » Inserm research team, which contributes to the Bordeaux Population Health research centre. He is concomitantly heading the Bordeaux Pharmacovigilance Centre.

Since 2015, he is coordonating the DRUGS-SAFE pharmacoepidemiology (Drugs Systematised Assessment in real-liFe Environment) which is missioned by the French drug agency (Agence Nationale de Sécurité du médicament, ANSM) to develop tools and methods allowing to improve the quality of pharmacoepidemiology research performed from French claims databases and to conduct specific pharmacoepidemiology studies.

Principales publications / Main publications :

1. Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, Bégaud B, Pariente A. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ. 2016;353:i2231.
2. Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S, Raschi E, Fourrier-Réglat A, Moore N, Sturkenboom M, Hazell On Behalf Of Investigators Of The Aritmo Consortium L; Investigators of the ARITMO Consortium. Sudden cardiac
and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies. Clin Pharmacol Ther. 2016;99:306-14.
3. Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, Pariente A, Bégaud B. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ. 2014;349:g5205.
4. Salvo F, Bazin F, Kostrzewa A, Bandre C, Robinson P, Moore N, Bégaud B, Pariente A. Fibrates and risk of cancer in tissues with high PPAR-α concentration: a nested case-control study. Drug Saf. 2014;37:361-8.
5. Salvo F, Raschi E, Moretti U, Chiarolanza A, Fourrier-Réglat A, Moore N, Sturkemboom M, De Ponti F, Poluzzi E, Pariente A. Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. Eur J Clin Pharmacol. 2014;70:617-25.
6. Billioti de Gage S, Bégaud B, Bazin F, Verdoux H, Dartigues JF, Pérès K, Kurth T, Pariente A. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345:e6231.
7. Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salamé G, Fourrier-Reglat A, Haramburu F, Bégaud B, Moore N; Association Française des Centres Régionaux de Pharmacovigilance (CRPV). Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf. 2012;35:855-64.
8. Pariente A, Fourrier-Réglat A, Ducruet T, Farrington P, Béland SG, Dartigues JF, Moore N, Moride Y. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012;172:648-53; discussion 654-5.
9. Pariente A, Fourrier-Réglat A, Bazin F, Ducruet T, Dartigues JF, Dragomir A, Perreault S, Moore N, Moride Y. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology. 2012;78:957-63.
10. Salvo F, Fourrier-Réglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, Caputi AP, Moore N, Sturkenboom MC, Pariente A; Investigators of Safety of Non-Steroidal Anti-Inflammatory Drugs: SOS Project. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther. 2011;89:855-66.

 

List of publications

logo_ISPED logo_Université-de-Bordeaux logo_SFR-santepublique-societe logo_CHU-Bordeaux logo_Institut-Bergonie logo_INRIA logo_ANRS logo_ARS logo_Charles-Perrens logo_IFSTTAR logo_HONcode